Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KLK7 | P49862 | 1/20 | 0.43 |
| ▸ | PARP14 | Q460N5 | 2/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16745350 | 0.98 | L3MBTL1 (0.43) | L3MBTL1MAPTJAK2TP53HTT | |
| SCHEMBL16745360 | 0.95 | L3MBTL1 (0.45) | L3MBTL1MAPTJAK2TP53HTT | |
| SCHEMBL16747993 | 0.94 | JAK2 (0.48) | L3MBTL1MAPTJAK2TP53HTT | |
| SCHEMBL16745425 | 0.91 | TP53 (0.46) | L3MBTL1MAPTJAK2TP53HTT | |
| SCHEMBL16747994 | 0.88 | TP53 (0.48) | L3MBTL1MAPTJAK2TP53HTT | |
| SCHEMBL18193064 | 0.87 | TP53 (0.41) | L3MBTL1MAPTJAK2TP53HTT | |
| SCHEMBL3600530 | 0.74 | L3MBTL1 (0.59) | L3MBTL1MAPTJAK2TP53HTT | |
| SCHEMBL16745397 | 0.72 | L3MBTL1 (0.55) | L3MBTL1MAPTCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL19451109 | 0.70 | PARP14 (0.56) | L3MBTL1MAPTJAK2TP53HTT | |
| SCHEMBL14728026 | 0.67 | CETP (0.64) | L3MBTL1MAPTJAK2TP53HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9481662-B2 | Seriniquinones, melanoma-specific anticancer agents | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-11-01 | — | — | US | disclosed |
| US-20150148314-A1 | SERINIQUINONES, MELANOMA-SPECIFIC ANTICANCER AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150148314-A1 | SERINIQUINONES, MELANOMA-SPECIFIC ANTICANCER AGENTS | SDHA, KLK3, BRDT | L3MBTL1 1229/4885MAPT 3301/4885JAK2 2811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.